2024-06-12T09:28:26-05:00 2023-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2023-01-01 861884515 DAVOS ALZHEIMER'S COLLABORATIVE INC DAVO 7035999617 155 EAST LANCASTER AVENUE WAYNE PA 19087 ANDREW HOLZAPFEL COO 7035999617 2024-06-12 1 ANDREW HOLZAPFEL 999009999 0 RICHARD J LOCASTRO CPA P00288314 3019519090 3 AAL1 IAL1 2023 2023-04-26 12:10:37Z GEORGE VRADENBURG 155 EAST LANCASTER AVENUE WAYNE PA 19087 8484685 0 X WWW.DAVOSALZHEIMERSCOLLABORATIVE.ORG X 2020 DC SEE PART III LINE 1. 3 2 0 3 0 0 9767900 8484685 0 0 0 0 0 0 9767900 8484685 2919719 1996537 0 0 0 0 0 0 17625 5181467 7013396 8101186 9009933 1666714 -525248 14995945 14067138 1586998 1186024 13408947 12881114 X DAC IS LEADING THE LARGEST GLOBAL RESPONSE OF ITS KIND, DRIVING SCIENTIFIC DISCOVERY AND ALIGNING HEALTH SYSTEMS TO HELP PEOPLE WORLDWIDE, INCLUDING THOSE IN LOW RESOURCED ENVIRONMENTS LEFT OUT OF PREVIOUS EFFORTS TO FIGHT ALZHEIMER'S. WE ARE COMMITTED TO TRANSFORMING ALZHEIMER'S RESEARCH, PREVENTION AND CARE THROUGH PROVEN PRIVATE-PUBLIC MODELS, SUCH AS GAVI, CEPI AND THE GLOBAL FUND. 0 0 6227466 1339037 HEALTHCARE SYSTEM PREPAREDNESS: DAC IS INVESTING TO TRANSFORM THE WAY HEALTHCARE SYSTEMS WORLDWIDE DETECT, DIAGNOSE AND TREAT ALZHEIMER'S. THE GOAL IS TO TAKE ADVANTAGE OF FUTURE INNOVATIONS TO IMPROVE THE QUALITY OF LIFE FOR PEOPLE EVERYWHERE. IN 2023, DAC CONTINUED TO ADVANCE 7 FLAGSHIP PROJECTS IN 6 COUNTRIES AS WELL AS SUPPORT AND MONITOR THE EXECUTION OF THE INITIAL GRANTS PROGRAM (12 GRANTS IN TOTAL). ADDITIONALLY, DAC DESIGNED OUR NEXT SET OF FLAGSHIP PROJECTS AND HAS BEEN WORKING CLOSELY WITH SITES ACROSS THE GLOBE TO LAUNCH THE PROGRAM IN 2024. 2017227 657500 GLOBAL COHORTS - DAC IS BUILDING GLOBAL COHORTS TO ADVANCE UNDERSTANDING OF ALZHEIMER'S AMONG DIVERSE POPULATIONS. THIS DATA WILL PROVIDE THE FOUNDATION FOR IDENTIFYING NEW BIOMARKERS AND DEVELOPING TARGETED TREATMENTS THAT WORK FOR PEOPLE WORLDWIDE. IN 2023, DAC ADVANCED OUR RESEARCH AGENDA BY:- PROVIDING MULTI-YEAR FUNDING TO WORLDWIDE FINGERS TO ADAPT AND CUSTOMIZE THEIR RISK REDUCTION PROTOCOL IN OVER 60 COUNTRIES.- COMPLETING THE FIRST TWO PHASES OF A LONG-TERM PARTNERSHIP WITH AGA KHAN UNIVERSITY IN NAIROBI, KENYA THAT IS VALIDATING COGNITIVE TESTS, SALIVA BASED POLYGENIC RISK SCORES AND NOVEL DIGITAL COGNITIVE ASSESSMENTS IN LOCAL EAST AFRICAN POPULATION WITH THE GOAL OF CREATING A CLINICAL TRIAL READY COHORT FOR TESTING PHARMACOLOGICAL AND NON-PHARMACOLOGICAL INTERVENTIONS. - ACQUIRING BLOOD SAMPLES FROM FIRST 300 OF A 3000 PERSON HIGHLY CHARACTERIZED (PET, CLINICAL DX) SOUTH KOREAN COHORT AND ACCESS TO 1,000 BLOOD SAMPLES FROM A LONG-STANDING COHORT IN THE LATAM/CARIBBEAN REGION FOR FURTHER ANALYSIS BY DAC'S NETWORK OF DIAGNOSTIC AND PHARMA PARTNERS TO GENERATE AD BLOOD BIOMARKER VALIDATION DATA.- BUILDING AND MAINTAINING A ROBUST PIPELINE OF COMMITTED COHORTS WITH DETAILED PROPOSALS MOUS, RANGING FROM COLOMBIA TO TANZANIA TO RURAL TEXAS, TO TEST AND VALIDATE EARLY COGNITIVE IMPAIRMENT DETECTION TECHNOLOGIES WITH A FOCUS ON REMOTE, UNDERSERVED AREAS TO FIND TOOLS THAT CAN MORE EASILY SCALE GLOBALLY. 144781 GLOBAL CLINICAL TRIALS - DAC IS MAINTAINING A NETWORK OF MORE THAN 30 EUROPEAN SITES ORGANIZED FOR ACCELERATING STUDIES AND IMPLEMENTING NOVEL TRIAL DESIGNS THAT IS BEING FUNDED BY A PHARMACEUTICAL COMPANY SPONSOR. DAC'S WORK THROUGH THE GLOBAL COHORT DEVELOPMENT PROGRAM SHOULD BE ABLE TO PROVIDE CLINICAL TRIAL READY POPULATIONS IN 2024 AND CREATE MORE OPPORTUNITIES FOR THE GLOBAL CLINICAL TRIAL PROGRAM. 8389474 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 1 19 0 1 0 0 1 SZ 0 0 0 0 0 0 0 0 0 0 X 3 2 0 1 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 0 0 0 X X X JENNIFER K SMITH 3012520563 2030 FLOWERING TREE TERRACE SILVER SPRING MD 20902 X GEORGE VRADENBURG CHAIR & PRESIDENT 20.00 2.00 X X 0 0 0 ANDREW HOLZAPFEL COO (SEE SCHEDULE O) 30.00 3.00 X X 0 0 0 FREDA LEWIS HALL TREASURER 1.00 1.00 X X 0 0 0 0 0 0 0 0 0 0 HIGH LANTERN GROUP 685 THIRD AVE 22ND FLOOR NEW YORK NY 10017 ADMIN, MARKETING, PR, AND IT 911000 WALLACE RES & DESIGN CORP 11 BLOOMFIELD AVE TORONTO ONTARIO CA M4L 2G2 HEALTHCARE SYSTEMS PREP. MGR 297330 BRIDGEABLE 101-1179 KING ST WEST TORONTO ONTARIO CA M6K 3C5 PROJ. MGMT FOR LAB & CONSULTING 275000 FAEGRE DRINKER 2200 WELLS FARGO CTR 90 S 7TH S MINNEAPOLIS MN 55402 LEGAL FEES 258715 1POINT618 INC 96 FLEMING WAY PRINCETON NJ 08540 COHORTS PROGRAM SUPPORT 243680 14 8484685 560400 8484685 8484685 0 0 0 X 1289183 1289183 707354 707354 911000 627200 283800 315382 246551 68244 587 127272 99404 27630 238 4615902 4598883 16841 178 636629 560656 69383 6590 1577 1013 564 7958 6691 1256 11 276208 171181 105027 106134 71134 25000 10000 11382 8890 2471 21 SUBSCRIPTION FEES 3952 1334 2618 9009933 8389474 602834 17625 14926469 13720960 16547 100000 52929 246178 14995945 14067138 1586998 1186024 1586998 1186024 X 12756730 12177430 652217 703684 13408947 12881114 14995945 14067138 X -525248 -2585 X 0 1 X 1 0 X 14514120 9767900 8484685 32766705 14514120 9767900 8484685 32766705 24123330 8643375 32766705 X FORM 990, SCHEDULE A, PART II, LINE 1 THE ORGANIZATION'S EXEMPTION WAS GRANTED ON 1/12/2021 MAKING 2021 A SHORT-YEAR. THEREFORE, THE 2021 COLUMN REPRESENTS A SHORT YEAR. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 8762365 277680 277680 8484685 0 8484685 9287945 277680 332 278012 9009933 0 9009933 PART XII, LINE 2D - OTHER ADJUSTMENTS: RELATED ORG. EXPENSES INCLUDED IN THE CONSOLIDATED FINANCIAL 332. STATEMENTS, BUT EXCLUDED FROM PART IX OF THE FORM 990. 1 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 64215 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 199250 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 88609 RUSSIA AND NEIGHBORING STATES 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 179920 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 175360 CENTRAL AMERICA AND THE CARIBBEAN 0 1 PROGRAM SERVICES RESEARCH SITE 389798 EAST ASIA AND THE PACIFIC 0 3 PROGRAM SERVICES RESEARCH SITE AND TRAVEL 122064 EUROPE (INCLUDING ICELAND & GREENLAND) 0 16 PROGRAM SERVICES ACCOUNTING SERVICES, CONFERENCE, LEGAL SERVICES, PROFESSIONAL FEES, RESEARCH SITE AND TRAVEL 572215 MIDDLE EAST AND NORTH AFRICA 0 3 PROGRAM SERVICES CONFERENCES, COLLABORATION AND MEETINGS 18342 NORTH AMERICA 0 6 PROGRAM SERVICES RESEARCH SITE AND TRAVEL 776779 SOUTH AMERICA 0 4 PROGRAM SERVICES RESEARCH SITE, CONFERENCES AND TRAVEL 651798 SOUTH ASIA 0 3 PROGRAM SERVICES PROJECT MANAGEMENT AND TRAVEL 13763 SUB-SAHARAN AFRICA 0 1 PROGRAM SERVICES RESEARCH SITE 223818 0 20 0 17 0 37 1791431 1684500 3475931 EAST ASIA AND THE PACIFIC SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 55000 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 9215 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 74250 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 125000 WIRE TRANSFER 0 NORTH AMERICA SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 74609 WIRE TRANSFER 0 NORTH AMERICA SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 14000 WIRE TRANSFER 0 RUSSIA AND NEIGHBORING STATES SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 179920 WIRE TRANSFER 0 SUB-SAHARAN AFRICA SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 175360 WIRE TRANSFER 0 8 0 1 0 0 0 0 0 PART I, LINE 2: GRANTEE PROVIDES WRITTEN REPORTS AT DESIGNATED TIMES OR MILESTONES. DAC PROVIDES A SAMPLE REPORT FOR GRANTEES TO USE UNLESS OTHERWISE SPECIFIED. GRANTEES ARE REQUIRED TO PARTICIPATE IN DAC FORUMS AND PROGRAMS. GRANTEE PROVIDES DAC WITH A ROYALTY-FREE LICENSE OR OTHER PERMISSION/AUTHORIZATION NECESSARY FOR DAC TO PUBLISH INSIGHTS AND KEY FINDINGS RESULTING FROM THE PROJECT, AS SHARED WITH DAC AND THE FORUMS AND PROGRAMS (ALL IN AGGREGATE OR SUMMARY FORM). GRANTEE WILL MAINTAIN COMPLETE AND ACCURATE RECORDS OF RECEIPTS AND EXPENDITURES CHARGED AGAINST THE GRANT THAT ARE SUFFICIENTLY DETAILED TO IDENTIFY THE USE OF FUNDS IN COMPLIANCE WITH THE GRANT AGREEMENT. DAC REPRESENTATIVES REVIEW THESE RECORDS AND THE RECORDS ARE TO BE MAINTAINED FOR A MINIMUM OF 3 YEARS AFTER THE COMPLETION OF THE GRANT. 1 ADVOCATE AURORA HEALTH 3075 HIGHLAND PARKWAY DOWNERS GROVE IL 60515 362167779 501(C)(3) 124911 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE AVANT INSTITUTE 9835 MONROE ROAD CHARLOTTE NC 28270 822461468 23084 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE INSTITUTE FOR HEALTHCARE IMPROVEMENT 53 STATE STREET 18TH FLOOR BOSTON MA 02109 383017223 501(C)(3) 224012 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE PHYSICIAN ASSISTANT FOUNDATION OF THE AMERICAN ACADEMY OF PHYSICIAN 2318 MILL ROAD SUITE 1300 ALEXANDRIA VA 22314 541071370 501(C)(3) 404676 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE TRUSTEES OF BOSTON UNIVERSITY 595 COMMONWEATLH AVE 700 WEST ENTRANCE BOSTON MA 02215 042103547 501(C)(3) 500000 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE BOSTON UNIVERSITY'S SCHOOL OF MEDICINE ANATOMY & NEUROBIOLOGY DEPARTMENT 25 BUICK STREET SUITE 200 BOSTON MA 02215 383017223 501(C)(3) 12500 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 5 1 PART I, LINE 2: GRANTEE PROVIDES WRITTEN REPORTS AT DESIGNATED TIMES OR MILESTONES. DAC PROVIDES A SAMPLE REPORT FOR GRANTEES TO USE UNLESS OTHERWISE SPECIFIED. GRANTEES ARE REQUIRED TO PARTICIPATE IN DAC FORUMS AND PROGRAMS. GRANTEE PROVIDES DAC WITH A ROYALTY-FREE LICENSE OR OTHER PERMISSION/AUTHORIZATION NECESSARY FOR DAC TO PUBLISH INSIGHTS AND KEY FINDINGS RESULTING FROM THE PROJECT, AS SHARED WITH DAC AND THE FORUMS AND PROGRAMS (ALL IN AGGREGATE OR SUMMARY FORM). GRANTEE WILL MAINTAIN COMPLETE AND ACCURATE RECORDS OF RECEIPTS AND EXPENDITURES CHARGED AGAINST THE GRANT THAT ARE SUFFICIENTLY DETAILED TO IDENTIFY THE US OF FUNDS IN COMPLIANCE WITH THE GRANT AGREEMENT. DAC REPRESENTATIVES AUDIT THESE RECORDS AND THE RECORDS ARE TO BE MAINTAINED FOR A MINIMUM OF 3 YEARS AFTER THE COMPLETION OF THE GRANT. X 3 191650 FMV X MEDICAL TESTS 3 368750 FMV 0 0 0 PART I, COLUMN (B): THE NUMBER IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS. FORM 990, PART VI, SECTION A, LINE 3 THE DAVOS ALZHEIMERS COLLABORATIVE, INC. (DAC) RETAINED AN INDEPENDENT CONTRACTOR, HIGH LANTERN GROUP, LLC (HLG), TO PROVIDE A SUITE OF MANAGEMENT SERVICES AND ADMINISTRATIVE SUPPORT, AS WELL AS THOSE DUTIES CUSTOMARILY PERFORMED BY AN ORG. CHAIR/PRESIDENT AND COO. DAC COMPENSATED HLG $911,000 FOR THOSE SERVICES. THE DUTIES OF THE CHAIR/PRESIDENT AND COO WERE PROVIDED TO DAC BY GEORGE VRADENBURG AND ANDREW HOLZAPFEL, RESPECTIVELY. OF THE $911,000 COMPENSATION PAID TO HLG BY DAC, $70,000 IS RELATED TO THE SERVICES PROVIDED BY ANDREW HOLZAPFEL. GEORGE VRADENBURG DOES NOT RECEIVE ANY SALARY OR PAYMENT. FORM 990, PART VI, SECTION A, LINE 8B THE ORGANIZATION HAS NO COMMITTEE WITH THE AUTHORITY TO ACT ON BEHALF OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY THE OUTSIDE ACCOUNTANTS. THE 990 WAS THEN REVIEWED WITH DAC'S COO AND CHAIR/PRESIDENT WITH THE AUDITORS. IT WAS THEN SHARED WITH THE BOARD AND FINALIZED UPON APPROVAL. FORM 990, PART VI, SECTION B, LINE 12C ALL OFFICERS, DIRECTORS OR TRUSTEES AND KEY EMPLOYEES(CONTRACTORS) ARE REQUIRED TO SIGN THE CONFLICT OF INTEREST POLICY AT THE FIRST BOARD MEETING OF THE YEAR AND UPON CONTRACTING OR DATE OF HIRE. IF A CONFLICT OF INTEREST IS FOUND, THE MATTER IS PRESENTED TO THE BOARD. THE APPLICABLE INTERESTED PERSON MAKES A PRESENTATION AT THE BOARD MEETING, BUT AFTER THE PRESENTATION, HE OR SHE REFRAINS FROM VOTING OR OTHERWISE ATTEMPTING TO EXERT ANY INFLUENCE ON WHETHER THE CORPORATION SHOULD PARTICIPATE OR NOT PARTICIPATE IN SUCH TRANSACTION AND LEAVES THE MEETING DURING THE DISCUSSION OF, AND VOTE ON, THE TRANSACTION OR ARRANGEMENT INVOLVING THE POSSIBLE CONFLICT OF INTEREST. AFTER EXERCISING DUE DILIGENCE, THE BOARD DETERMINES WHETHER THE CORPORATION CAN OBTAIN WITH REASONABLE EFFORTS A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY POSSIBLE UNDER CIRCUMSTANCES NOT PRODUCING A CONFLICT OF INTEREST, THE BOARD DETERMINES BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN THE CORPORATION'S BEST INTEREST, WHETHER IT IS FAIR, REASONABLE, AND THE RESULT OF ARM'S-LENGTH BARGAINING, AND WHETHER IT REFLECTS REASONABLE INVESTMENT CRITERIA OR PAYMENTS FOR GOODS AND SERVICES, FURTHERS THE CORPORATION'S PURPOSES AND DOES NOT RESULT IN PRIVATE INUREMENT, IMPERMISSIBLE PRIVATE BENEFIT OR AN EXCESS BENEFIT TRANSACTION. IN CONFORMITY WITH THE ABOVE DETERMINATION, THE BOARD OR COMMITTEE MAKES ITS DECISION IN WRITING AND ON THE RECORD AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G COHORT DATA ANALYSIS: PROGRAM SERVICE EXPENSES 243,680. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 243,680. PROJECT MANAGEMENT: PROGRAM SERVICE EXPENSES 275,000. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 275,000. HEALTHCARE SYSTEM: PROGRAM SERVICE EXPENSES 297,330. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 297,330. PROGRAM CONSULTING: PROGRAM SERVICE EXPENSES 1,358,766. MANAGEMENT AND GENERAL EXPENSES 16,841. FUNDRAISING EXPENSES 178. TOTAL EXPENSES 1,375,785. RESEARCH FEES: PROGRAM SERVICE EXPENSES 2,424,107. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,424,107. FORM 990, PART XI, LINE 9: CURRENCY EXCHANGE LOSS -2,585. DAVOS ALZHEIMER'S COLLABORATIVE (GENEVE) COURS DE RIVE 13 C/O PESTALOZZI AV GENEVE SZ 1204 PROMOTE HEALTH BY DEVELOPING RESEARCH ON BRAIN HEALTH. SZ N/A N/A DAC 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 DAVOS ALZHEIMER'S COLLABORATIVE (GENEVE) B 241 ACTUAL COST